Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
SGPthis companySpyGlass Pharma, Inc. Common Stock	$37.24	-21.12×	-8.52×	0×	-19.05×	-91.4%	0.0%	0.0%	0.0%	40.3%	-38.6%	-4.0%	-0.02×	2.41×	0×	12.67×	0.0%	—	—	2	C
EYPTEyePoint Pharmaceuticals, Inc.	$0.36	-5.76×	4.37×	42.66×	-5.49×	-1218.8%	93.4%	-776.0%	-739.4%	-75.8%	-74.0%	-18.2%	0.07×	0.34×	0×	8.88×	0.0%	2	-11.09	1	C-
GKOSGlaukos Corporation	$233.40	-34.42×	9.84×	12.73×	-44.54×	-132.8%	77.5%	-17.1%	-37.0%	-28.6%	-10.6%	-0.8%	0.21×	-0.33×	-18.71×	4.69×	0.0%	4	31.48	1	C-
OCULOcular Therapeutix, Inc.	$6.46	-8.55×	3.47×	43.86×	-6.47×	-101.4%	87.3%	-521.0%	-513.2%	-40.6%	-35.5%	-9.5%	0.12×	2.63×	-22.82×	15.39×	0.0%	2	2.82	1	C-
RXSTRxSight, Inc.	$4.61	-10.97×	1.56×	3.19×	-11.81×	-4900.6%	76.6%	-35.8%	-29.0%	-14.1%	-16.8%	-4.5%	0.04×	0.25×	-1,204.75×	10.95×	0.0%	2	-0.63	2	C+
SGHTSight Sciences, Inc.	$10.38	-10.72×	6.47×	5.35×	-11.05×	-82.2%	86.2%	-48.0%	-49.7%	-60.1%	-35.4%	-7.2%	0.64×	1.56×	-7.21×	10.22×	0.0%	4	1.35	1	C-
Peer median	—	-10.72×	4.37×	12.73×	-11.05×	-132.8%	86.2%	-48.0%	-49.7%	-40.6%	-35.4%	-7.2%	0.12×	0.34×	-18.71×	10.22×	0.0%	2	1.35	1	—